Corrections or additions?
These articles were prepared for the March 9, 2005 issue of U.S. 1
Newspaper. All rights reserved.
Medico joins several other big generic manufacturers in central New
Jersey, namely Accumed, Guardian Drug, and Ranbaxy. Accumed and
Guardian focus on over the counter generics, and Ranbaxy does both OTC
and "ethical" or prescription drugs.
Notable among the prescription drug generic manufacturers are Sandoz
(formerly Geneva Pharmaceuticals, with 300 people divided between
Dayton and the Carnegie Center) and Stada Pharmaceuticals, with 30
people at Cedar Brook Corporate Center. Others are Apothecon, a
Bristol-Myers Squibb generic manufacturer on Scudders Mill Road;
Xechem, which researches and produces proprietary and generic drugs on
Jersey Avenue in New Brunswick; and Neil Laboratories, located at 55
Lake Drive in Hightstown.
Yogsh Besai, quality control manager. 609-883-1818; fax, 609-883-2288.
In 100,000 square feet on Brunswick Pike, the former Heinemann
Electric facility, Accumed makes such generic products as antacids,
laxatives, enzyme supplements, stomach remedies, nasal and throat
sprays, oral care items, and topical products. According to its
website, recent products include a tooth whitening gel that competes
with Colgate’s Simply White, soluble fiber caplets similar to
Citrucel, Slide-a-Mint antibacterial breathstrips, and a formula for
PeriColace, a laxative plus stool softener.
Qpharma, which operates within Accumed’s headquarters on Brunswick
Pike, has obtained a $.5 million loan guarantee from the New Jersey
Economic Development Authority for a $2.04 million Sun National Bank
loan. At the time of the loan (U.S. 1, October 24, 2004), Qpharma was
said to be making prescription generic nasal spray formulations and
oral liquid products, and it was going to use the money for equipment
and working capital. The company did not return two calls from a
08810. Arvind Dhruv, president. 609-860-2600; fax, 609-860-8008. Home
Guardian Drug is a 20-year-old private label manufacturer of over the
counter pharmaceuticals, chiefly generic stomach remedies. It bought
the former Block Drug building in Dayton with the help of a $7.5
million bond from the New Jersey Economic Development Authority and
moved from 72 Prince Street in Trenton in 2000. Among its products is
a re-formulated Ex-Lax, and its top sellers – of a couple of million
units a year – are the Tums look-alikes, antacids with calcium.
"Though we sell to certain customers that export, our major market is
the big retail chains," says Vinima Karov, spokesperson. The chains
insist on national brand equivalents, or NBEs. "It has to match in
ingredients, quality, taste, and look, and it has to be as close to
the packaging as possible." "We also do contract manufacturing for
Princeton 08540. Dipak Chattaraj, president. 609-720-9200; fax,
609-720-1155. Home page: www.ranbaxyusa.com
With 9,100 global employees, Ranbaxy Laboratories Ltd. is India’s
largest pharmaceutical company. Last February it marked sales of $1
billion for a 12-month period. It sells 93 products, representing
eight therapeutic classes, in more than 100 countries. It has
factories in seven countries and operates in 34 countries.
Ranbaxy Inc., based on College Road, is its wholly owned subsidiary.
Ranbaxy has more than 260,000 square feet for manufacturing, including
its over the counter manufacturing site, Ohm Laboratories on Black
Horse Lane in North Brunswick, and the OTC and prescription sites on
Livingston Avenue and Terminal Road in New Brunswick. All these
facilities make solid dosages; liquids are made in upstate New York.
Ohm Laboratories produces private label, finished consumer goods. This
means that the product is ready to be put on the shelf by large retail
outlets, mass merchandisers, and food outlets. In the prescription
area, Ranbaxy has a generic version of accutane, an acne medication,
and one for augmentin, a broad spectrum antibiotic used for middle
ear infections. It is marketing the generic equivalent to Schering’s
Claritin, known as Loratadine.
Last month Ranbaxy received tentative approval from the Food and Drug
Administration to make and market a generic version of a treatment for
dementia associated with Alzheimer’s. Promoted by Teaneck-based Eisai
and Pfizer, Aricept’s patent does not expire until 2010. Only then
will Ranbaxy be able to make donepezil hydrochloride tablets in 5 and
10 mg doses. "We were the first to file, so according to the 1983
Waxman-Hatch law, that will give us exclusivity in the marketplace for
180 days," says a spokesperson.
Princeton 08540. John Sedor, CEO. 609-627-8500; fax, 609-627-8682.
Home page: www.us.sandoz.com
Geneva Pharmaceuticals is now owned by Sandoz, which has an R&D center
in Dayton and a headquarters for staff operations at the Carnegie
Center. Manufacturing operations are in Colorado.
Among its recent launches is a generic Rebetolr (Ribavirin), which is
used in combination with interferon to treat hepatitis C. "People with
hepatitis C who need this drug therapy will now be able to obtain it
more readily and receive excellent patient support," said CEO John
Sedor in a press release.
Brook Corporate Center, Cranbury 08512. Christian Scheiner, president.
609-409-5999; fax, 609-409-5995. Www.stadausa.com
Germany-based Stada bought the portfolio and other assets of Mova
Laboratories in 2002, and it made other acquisitions from Wyeth and
ESI Lederle. Now it markets and sells generic drugs and is among the
top 10 generics suppliers in Europe. It also develops branded and
In this country it offers prescription antibiotics, non-steroidal
anti-inflammatory drugs (NSAIDs), anti-hypertensives, and
ulcer/heartburn medications (H2 receptor antagonists) in capsule,
tablet and pediatric dosage forms. Last year it launched methotrexate
product, Rheumatrex Dose Pack, which it had bought from Wyeth. Stada
aims to focus on the rheumatology market.
Avenue, Building B, Suite 310, New Brunswick 08901-3279. Ramesh C.
Pandey, chairman, president, CEO. 732-247-3300; fax, 732-247-4090.
Home page: www.xechem.com
Founded in 1990, Xechem does research, development, and production of
generic and proprietary drugs, including ginseng and melatonin
products. Among Xechem’s generic drugs are Vancomycin, Paclitaxel, and
Bleomycin. Paclitaxel has been compared with Bristol-Myers Squibb’s
Taxol for treating refractory ovarian and breast cancer. In addition
to labs in Gaithersburg, Maryland, it has sites in India, Hong Kong,
Junction Yuqing Guo, scientist. 732-329-2879; fax, 732-329-2801. Home
Austarpharma is researching and developing generic drugs and new
chemical entitites, focusing on new drug delivery routes. It plans to
staff up to 30 people at Princeton Corporate Plaza.
Yuquing Guo, the scientist in charge, graduated from Beijing
University in 1970 and earned his PhD in physical chemistry from the
SUNY Buffalo. There he met fellow Austarpharma scientist Sam Lu, who
went to Fudan University in Singapore, Class of 1984.
The company also has a warehouse, nearly 50,000 square feet, in
Columbus Circle, Raritan, and plans to build a development center with
production machines and a chemistry lab, but has not started
Suite M1, Monmouth Junction 08852. 732-748-8882; fax, 732-748-8929.
Home page: www.apicore.com
Apicore was founded in 2004 to develop and manufacture the active
pharmaceutical ingredients used for generic pharmaceuticals. It moved
to Princeton Corporate Plaza and currently has nine workers in 3,200
Sanjay Bharvav, vice president of operations, has 20 years experience
manufacturing active pharmaceutical ingredients in this country and in
India, and he formerly worked for the fourth largest company in India.
Bharvav is a 1981 graduate of the University of Gujarat and has a
master’s degree from the same university.
Plaza, Suite H-6, Monmouth Junction 08852. Jay Chigurupati PhD MBA,
chief executive officer. 7332-438-1622. Home page: www. zeno
Zenotech is a generic pharmaceutical company that also does contract
research. According to its website, it will launch generic monoclonal
antibody therapeutics soon. It has received clearance to make a
generic version, Rituximab, of Genentech’s Rituxan (protein’s name
Rituximab) and plans to market this in India next year.
101, Princeton 08540. Joseph Renner, CEO. 609-275-5125; fax,
609-716-6002. Home page: www.zydususa.com
Based in India, with 6,000 employees worldwide, Zydus has been
acquiring companies and growing quickly. With 20 employees at the
Carnegie Center, Zydus USA aims to provide finished dosage
formulations to the generic market. It expanded from 300 Alexander
Road last year to 9,400 square feet at the Carnegie Center..
Founded as Cadila, it was renamed ‘Zydus,’ according to the company’s
website, because the name "combines the ethos of the Greco-Roman God
Zeus and the dawn of a new era. Zydus like Zeus also symbolizes the
group’s aspirations to contribute to the welfare of the people and to
society at large."
Plainsboro 08536. Prasada Reddy Kambham, vice president. 609-716-1190;
fax, 609-716-1142. Home page: www.aurobindo.com
This U.S. office of a generic drug manufacturer was founded in 1988
and is based in Hyderabad. It has had three products approved by the
U.S. Food and Drug Administration for marketing in the U.S. Just
approved as an Abbreviated New Drug Application (ANDA) is a diabetes
Its product portfolio includes antibiotics, anti-retro virals, CVS,
CNS, gastroenterologicals, and anti-allergics, and it markets products
to more than 100 companies. Vice president Prasada Reddy Kambham has
five employees at Princeton Meadows Office Center. He went to SV
University in South India, Class of 1988, and has a master’s degree
from City University of New York.
Suite 210, Princeton 08540. Terry Coughlin, president. 609-514-1444;
fax, 609-514-1402. Home page: www.glenmarkus.com
Glenmark Pharmaceuticals has moved from 4390 Route 1 South to
Princeton Corporate Center, where it has 10 employees. The U.S.
subsidiary is helping to file ANDAs (abbreviated new drug
applications) and market-finished formulations in the U.S. market. The
firm will also register its bulk drugs – the key ingredients that lend
medicines their potency – with the US Food & Drug Administration,
according to the company’s website.
The company’s website defines its target market: "The international
generics market offers a huge opportunity for Indian pharma companies.
As many as 60 products with more than $40 billion in sales are
expected to lose their patents over the coming decade. In the US
alone, this generics opportunity is expected to be worth $19 billion
"Indian companies are moving the value chain by moving to developed
markets and from bulk drugs to formulation exports. As a result,
Indian companies are expected to produce six of the top ten drugs that
are scheduled to lose their patent protection over the next five
years," says the company in the website statement.
Corrections or additions?
This page is published by PrincetonInfo.com
— the web site for U.S. 1 Newspaper in Princeton, New Jersey.